VALN — Valneva SE

Company context · prepared 2026-08-11 · company sweep 2026-08-11 · USD · framework v5.6.1

How to read this. Written for a reader who has not studied pharmacology or finance. General terms are defined once in framework/04-glossary.md. Tags: [VERIFIED — source] / [UNVERIFIED] / [WEB ESTIMATE — source, date].

Program analyses for this company are the sub-folders listed in C.2.

Currency note. Valneva is a French company. It reports its accounts in euros (EUR), and its Nasdaq quote is in US dollars (USD). Every euro figure below is given as the company filed it and then converted at EUR/USD 1.1542, the 2026-08-11 close [VERIFIED — Yahoo Finance chart API, EURUSD=X, read 2026-08-11]. The rate is stated once here so that any figure below can be re-derived. Converting a 2026-03-31 balance at a 2026-08-11 rate is an approximation, and it is labelled as one wherever it matters.

Share-class note. One Nasdaq-listed American Depositary Share (ADS, the US-traded certificate that stands for shares in a foreign company) represents two Valneva ordinary shares [VERIFIED — Valneva IPO and follow-on offering prospectuses, SEC Form 424B4 2021 and subsequent offerings, read 2026-08-11]. Every per-share price in this document is a per-ADS price, because that is what the $5.30 quote and the price cache are. Every share count is in ordinary shares unless it says ADS-equivalent. Getting this backwards doubles or halves the market capitalisation, so it is stated before any number that depends on it.

C.0 Company-tier coverage — CLEARED

Verdict: CLEARED. Every mandatory company-tier row was called and returned. Two rows returned empty results that a naive reading would take for silent failures; both were independently cross-checked and both are real findings about this company rather than gaps in the sweep.

C.1 What the company is

Valneva SE is a French vaccine company based in Saint-Herblain, near Nantes. It is not a single-asset biotech: it already sells three approved vaccines and had product sales of €157.9 million (about $182.2 million) in 2025 [VERIFIED — Valneva FY2025 results release, 2026-03-18]. Those products are IXIARO (against Japanese encephalitis, a mosquito-borne brain infection), DUKORAL (an oral vaccine against cholera and travellers’ diarrhoea) and IXCHIQ (against chikungunya, a mosquito-borne viral disease).

Alongside that commercial base it runs a development pipeline of seven BPIQ-recorded programs, of which two currently carry a disclosed upcoming catalyst: VLA15 (a Lyme disease vaccine, partnered with Pfizer and now branded LB6V) and S4V2 (a vaccine against shigellosis, a severe bacterial diarrhoea, partnered with LimmaTech Biologics).

The company is under visible commercial stress. In 2026 it cut its product-revenue guidance from €145–160 million to €135–150 million, launched a restructuring to remove 10–15% of its global workforce and 25–35% of operating expenses versus 2025, and withdrew its US licence applications for IXCHIQ after the FDA suspended that vaccine’s US licence [VERIFIED — Valneva Q1 2026 results release, 2026-05-13; Valneva release 2026-01-19]. The shares sit at $5.30, which is 7.3% of the way up a 52-week range whose top is $12.25.

C.2 Pipeline — every program

Every row returned by fetch_company_drugs on 2026-08-11, including the discontinued one. Catalyst dates are reported as catalyst_date_text; the “to a day?” column is yes only where that text names a day (01-rules.md rule 23). Six of the seven rows read “TBA”, which BPIQ stores as a null date.

Two rows carry a catalyst; only one carries a date. VLA15 (13398) has has_catalyst: true with a null catalyst_date and catalyst_date_text “TBA”. That has a direct consequence for the S4V2 analysis: the catalyst-clustering computation cannot see a row with no date, so VLA15 does not enter the conflict set, and S4V2’s attribution reads CLEAN for a mechanical reason rather than because nothing else can land near it. This is stated again in the program document and in C.8.

C.3 Financial position

Why the recomputed burn understates research spend. Valneva spent €15.2M on research and development in Q1 2026 alone [VERIFIED — Q1 2026 results release], roughly €5.1M a month, against a €1.5M/month net cash decline. The difference is product gross margin funding most of the research. This matters for the S4V2 read: the readout does not sit in front of a financing cliff the way a pre-revenue biotech’s would.

BPIQ’s burn fields disagree with each other and with both figures above. The connector reports ttm_burn −18,860,000, qtr_burn −313,000 and monthly_burn −104,333. A trailing-twelve-month burn of 18.86M implies 1.57M a month, not 0.104M; and a quarterly burn of 0.313M is inconsistent with a €4.4M quarterly cash decline. None of the three is used above. See C.8.

Dilution history. Every equity raise and every registration in the last 24 months, plus the debt refinancing that sits alongside them.

The June registrations are not new dilution on top of April’s. 15,893,817 placement shares plus 15,893,817 warrant shares is 31,787,634 — which is the 31.6–31.8M being registered. The F-3 and the 424B3 make the April placement’s shares and warrant shares freely resellable; they do not create a second tranche. Reading them as a fresh 17% overhang on top of the April raise would double-count the same shares. [VERIFIED — arithmetic over the 2026-04-30 release and the two EDGAR filings]

The warrants are the dilution mechanism to watch, and they are tied to Lyme, not to Shigella. Each warrant is exercisable at €2.96 per ordinary share (€5.92 per ADS ≈ $6.83 per ADS) and becomes exercisable on FDA approval of the LB6V Lyme disease vaccine candidate, running to a March 2028 backstop [VERIFIED — Valneva release 2026-04-30; SEC Form 6-K 2026-05-01]. Two consequences. First, $6.83 per ADS is a live, contractual level at which roughly 7.9M ADS-equivalents of new stock appears — a real cap on any rally that reaches it. Second, the trigger is a Lyme approval, so the S4V2 readout does not fire it.

Is a raise likely before the S4V2 catalyst? No. The company raised €37M in cash three months ago from eight named institutional investors, holds about $164M of cash, sells €135–150M of product a year, and has just cut a quarter to a third of its operating expenses. The ATM remains open and could be tapped opportunistically, but nothing forces a raise into this readout.

Share count, reconciled. 173,539,745 ordinary shares at 2025-12-31 [VERIFIED — EDGAR XBRL dei:EntityCommonStockSharesOutstanding, Form 20-F filed 2026-03-17] plus the 15,893,817 placement shares gives 189,433,562, against the company’s declared 189,771,237 ordinary shares at 2026-07-31 [VERIFIED — Valneva shares-and-voting-rights declaration, 2026-08-05]. The 337,675-share remainder is ordinary option and ATM activity. Total voting rights are 204,363,556, higher than the share count because French law grants double voting rights to long-held registered shares; voting rights are not a share count and are not used as one anywhere below.

C.4 Valuation frame

Plain reading. The shares are within 12% of their 52-week low and 57% below their 52-week high. Almost the whole decline is dated: the stock closed at $10.32 on 2026-03-20 and $6.49 on 2026-03-23, the session the Lyme Phase 3 result was published (C.7). The market is not pricing much optimism into anything at this level, which is the single most important fact for how a Shigella surprise would be received.

Liquidity. Average dollar volume on the Nasdaq line over the last 60 trading days is about $152,000 a day [VERIFIED — computed from data/prices/VALN.json]. That is extraordinarily thin for a company of this size, and it is an artifact of the dual listing: Valneva’s primary market is Euronext Paris, and the Nasdaq ADS line carries a small minority of the volume. Any statement below that depends on liquidity says which line it is talking about.

C.5 Ownership and flow

Insider and holder flow, in plain sentences. There is no open-market insider buying or selling to read, because the reporting obligation that would produce it does not apply to this issuer. What exists instead is the April 2026 placement, and it is more informative than a Form 4 would have been: eight named specialist healthcare funds, several of them new to the register, bought 15,893,817 new shares at €2.33 each — about $5.38 per ADS-equivalent, within 2% of today’s $5.30. That is a large, recent, arm’s-length institutional clearing price for this equity, struck after the Lyme Phase 3 collapse and before this readout, and it is used as a scenario anchor in the program document. On the other side, the French state investment vehicles adjusted their stakes in March 2026 and D.E. Shaw is disclosed net short. BPIQ’s short_float field reads 0.00224; its units are unconfirmed per 02-connectors.md, but read as 0.224% it sits in the same range as the FINRA figure derived above, so the two do not contradict each other.

C.6 Options chain and its readability

Plain takeaway: there is no options chain. Valneva has no exchange-listed options at all, so the chain cannot price this event, cannot bracket it, and cannot be quoted at any precision. This is not a thin chain or an artifact-ridden one — it is an empty one, confirmed twice.

The consequence for the program document is stated there rather than assumed: the expected move around the S4V2 readout is estimated from this ticker’s own past catalyst reactions (C.7), never from an options-implied move, because no such number exists.

C.7 Reaction to past catalysts

Moves are computed from data/prices/VALN.json and given two ways, because they differ and the difference is informative: close-to-close (previous session’s close to this session’s close, which captures a gap opening) and open-to-close (the intraday move, which is what BPIQ’s intra_day_price_change_percent reports). Every row is cross-checked against the same-day press feed.

What this table says about how this equity trades a readout. Three patterns hold across every row. The move happens in the opening gap, not during the session, so an intraday figure systematically understates it. Positive data is not sufficient — the largest move in the table is a 37% fall on a successful Phase 3. And magnitude tracks materiality: the dominant asset produced −37%, the revenue base produced −19%, and everything else produced single digits.

C.8 Company data-quality flags

1. BPIQ’s historical-catalyst feed omits the two largest price reactions this equity has produced. Neither the 2026-03-23 Lyme Phase 3 topline (−37.11%) nor the 2025-08-25 FDA licence suspension (−18.99%) appears in the fourteen rows returned. Both were recovered from the press feed and priced from the committed cache instead. Any analysis that built C.7 from the catalyst feed alone would conclude that this stock’s worst catalyst reaction was about −3%.
2. BPIQ’s intra_day_price_change_percent disagrees with the price cache on two of the five rows that could be checked. 2025-11-04 (BPIQ +2.66% against the cache’s −1.41% open-to-close) and 2025-09-03 (BPIQ +3.85% against −0.79%). The other three match the cache’s open-to-close figure to the basis point, so the field’s definition is right and its values are not uniformly reliable. The 2025-09-03 row also carries news_published_at 2025-11-04 against catalyst_date 2025-09-03. Every figure in C.7 is the cache’s, not BPIQ’s.
3. BPIQ’s market_cap cannot be reconciled with the filed share count. 541,234,112 ÷ $5.30 implies about 102.1M units, against 189,771,237 ordinary shares (94,885,619 ADS-equivalents). The difference is 7.6% and its cause is not established: it is close to, but not equal to, half the total voting-rights figure of 204,363,556. C.4 therefore derives market capitalisation from the filed share count and the confirmed 1:2 ADS ratio rather than reading the field. The known previous-close bug in 02-connectors.md does not bite today, because the previous close and the last price are both 5.30.
4. BPIQ’s cash and enterprise-value fields appear to carry euro amounts without a currency label. cash is 105,265,000 against the company’s disclosed **€**105.3 million. Treating that as dollars would overstate US-dollar cash by about 15%. Every figure in C.3 and C.4 states its currency and its conversion rate.
5. BPIQ’s three burn fields are mutually inconsistent (ttm_burn −18,860,000, qtr_burn −313,000, monthly_burn −104,333: the first implies 1.57M a month, the third says 0.104M). None is used; C.3 recomputes the burn from the two disclosed cash balances and says plainly why even that figure is not a research burn rate.
6. cash_runway_end_date is a sentinel, not a date. BPIQ carries 2109-02-11 for this ticker, which means the field is unset. It is reported as “no date”, never as an 83-year runway.
7. fetch_company_options_data and fetch_company_insider_transactions both return empty results, and in this case both are true. Neither is the silent-failure pattern 02-connectors.md records for the insider connector on TLSA. VALN has no listed options (Yahoo chain confirms zero expiries and zero strikes) and, as a foreign private issuer, no Section 16 filings exist to report (EDGAR filing history confirms no Form 3, 4 or 5). Both were retried per the retry policy before being recorded.
8. tute_own of 3.62% understates institutional ownership by a wide margin, because it measures US-registered holdings of the ADS line while the register is dominated by European holders and by Pfizer’s 2022 stake. It is quoted in C.5 with that limit stated rather than used as a float input.
9. The pipeline’s second has_catalyst row carries no date. VLA15 (13398) reads catalyst_date: null, catalyst_date_text: "TBA". Because lib/clustering.mjs derives no window from a row with no date, VLA15 cannot enter the catalyst-clustering conflict set, and S4V2’s attribution status of CLEAN therefore rests on an absence of data rather than on a measured separation. Pfizer’s Lyme regulatory submissions are expected during 2026 and could land inside the S4V2 readout window. The program document states this in its own attribution section and in its stock-direction call rather than presenting CLEAN at face value.
10. The April 2026 offering is reported at two different sizes by two sources, and both are right. The 2026-04-30 release headlines €84 million; the Q1 2026 results release says €37.0 million of gross proceeds. The reconciliation is that €37.0M is cash at closing and up to €47M more arrives only if every warrant is exercised. Both figures are carried in C.3, neither is averaged, and the headline figure is never used as cash received.